Efficacy and Safety of Hebenrun in Patients With Type 2 Diabetes

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorJiangxi University of Traditional Chinese Medicine

About this trial

This study aims to evaluate the efficacy and safety of Hebenrun (a functional food based on natural grain bran) combined with metformin in patients with type 2 diabetes mellitus (T2DM). The study hypothesis is that Hebenrun combined with metformin will achieve a higher complete discontinuation rate of oral hypoglycemic drugs compared to metformin alone. A total of 110 T2DM patients will be randomly assigned (1:1) to the study group (metformin + Hebenrun) or the control group (metformin alone) and followed for 48 weeks. The primary outcome is the complete discontinuation rate of oral hypoglycemic drugs at the end of follow-up.

Eligibility criteria

Qualifiers

Meets the Western medicine diagnostic criteria for type 2 diabetes (T2DM), referring to the Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 Edition). If typical diabetes symptoms are present (such as polydipsia, polyuria, polyphagia, unexplained weight loss), meeting any one of the following can confirm the diagnosis: fasting blood glucose (FBG) ≥7.0 mmol/L; random blood glucose ≥11.1 mmol/L; oral glucose tolerance test (OGTT) 2-hour blood glucose ≥11.1 mmol/L; glycated hemoglobin (HbA1c) ≥6.5%. If typical diabetes symptoms are lacking, two of the above blood glucose indicators at the same time point or at two different time points (excluding random blood glucose) need to reach or exceed the diagnostic cut-off point to diagnose diabetes.

Age 18-65 years, glycated hemoglobin (HbA1c): 6.5%-8.5%.

Good patient compliance, cooperation with treatment and follow-up.

The research has been approved by the hospital ethics committee, and all patients voluntarily participate and sign informed consent.

Disqualifiers

Type 1 diabetes, gestational diabetes, and special types of diabetes.

History of acute diabetic complications (ketoacidosis, hyperosmolar coma, lactic acidosis).

Major organ diseases (severe heart, liver, kidney dysfunction), malignant tumors, or severe mental disorders.

Contraindications or allergy history to any component of Hebenrun.

Trial design

Treatments tested in this trial

  • Metformin
  • Hebenrun

Treatment groups

110 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Jiangxi University of Traditional Chinese Medicine

Lead sponsor

The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine

Collaborator